NPM1 and myeloproliferative neoplasm: Schnittger et al. found that NPM1 mutation was observed in 6/67 secondary AML (s-AML) patients with a history of MPN and concluded that the NPM1 mutations are not only a key factor in the initiation of de novo AML but may contribute to s-AML following MPN [35].